Related Experiment Video
Updated: Apr 14, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Emerging paradigms in targeted treatments for Asian patients with NSCLC
E-E Ke1, Qing Zhou, Yi-Long Wu
1Southern Medical University , Guangzhou, Guangdong 510515 , PR China.
Introduction:
EGFR-targeted drugs have been successfully approved in many countries and have demonstrated higher efficacy and lower toxicity than chemotherapy in molecularly defined subgroups of patients. Significant advances in clinical trials and studies focusing on targeted therapies have rapidly developed in Asia.
Areas Covered:
In the present review article, all of the published data or meeting abstracts on completed or ongoing trials of targeted treatment for Asian patients with NSCLC were collected and analyzed.
Expert Opinion:
Routine molecular testing has been used clinically to identify mutations/fusions and guide patient selection for targeted therapies. Based on the evidence presented, we provided up-to-date treatment recommendations for Asian patients with advanced NSCLC. Future directions, including dividing Del19 and L858R patients into two distinct populations, will optimize therapeutic strategies for L858R patients and may inform rational trial design by considering the proportion of type of sensitive EGFR mutation as a stratification factor. Another important aspect to consider involves how to monitor resistance to TKIs, which will improve the outcome for lung cancer patients with driver gene mutations.
Insights
Targeted therapies show improved efficacy for Asian patients with non-small cell lung cancer (NSCLC). Molecular testing and personalized treatment strategies, including monitoring TKI resistance, are crucial for optimizing outcomes in EGFR-mutated NSCLC.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Trials
Background:
- Epidermal Growth Factor Receptor (EGFR)-targeted drugs offer superior efficacy and reduced toxicity compared to chemotherapy in specific patient groups.
- Asia has seen rapid advancements in clinical trials and research for targeted cancer therapies.
Purpose of the Study:
- To review and analyze completed and ongoing targeted treatment trials for Asian patients with Non-Small Cell Lung Cancer (NSCLC).
- To provide updated treatment recommendations for Asian patients with advanced NSCLC based on current evidence.
Main Methods:
- Systematic collection and analysis of published data and meeting abstracts from trials involving targeted treatments for Asian NSCLC patients.
- Review of molecular testing data to identify mutations and guide therapy selection.
Main Results:
- EGFR-targeted therapies have demonstrated significant efficacy in molecularly defined subgroups of Asian NSCLC patients.
- Routine molecular testing is integral to identifying actionable mutations and selecting appropriate patients for targeted treatments.
Conclusions:
- Personalized treatment strategies, guided by molecular testing, are essential for optimizing outcomes in Asian patients with advanced NSCLC.
- Future research should focus on stratifying patients by specific EGFR mutations (e.g., Del19 vs. L858R) and monitoring resistance to Tyrosine Kinase Inhibitors (TKIs) to further improve patient prognosis.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...